Somaserve raises £2.1m in an investment co-led by Origin Capital to develop targeted drug delivery technologies.
Origin Capital co-led the £2.1m funding round for the nanoparticle technology developer.
£2.1M
Somaserve develops specialised nanoparticle technologies designed to transport pharmaceutical and therapeutic agents to specific cell types.
Somaserve has secured £2.1m in a funding round co-led by Origin Capital. The company develops specialised nanoparticle technologies to deliver pharmaceutical and therapeutic agents directly to targeted cell types. The capital will support further development of its drug delivery platform.
The investment represents a key milestone for the firm as it advances its targeted delivery capabilities for the pharmaceutical sector.
